
BeiGene, Ltd. BGNE
Annual report 2025
added 02-26-2026
BeiGene, Ltd. Operating Cycle 2011-2026 | BGNE
Annual Operating Cycle BeiGene, Ltd.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 52.6 | 49.5 | 39.4 | 84.6 | 84.3 | 382 | 72.5 | 106 | 59.6 | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 382 | 39.4 | 103 |
Quarterly Operating Cycle BeiGene, Ltd.
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 52.8 | 51.6 | 56.9 | - | 50 | 47.4 | 48.1 | - | 338 | 341 | 372 | - | 372 | 374 | 442 | - | 303 | 288 | 237 | 55.1 | 446 | 653 | 495 | 114 | 259 | 173 | 200 | 63.9 | 239 | 308 | 371 | 148 | 525 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 653 | 47.4 | 256 |
Operating Cycle of other stocks in the Biotechnology industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Apellis Pharmaceuticals
APLS
|
115 | $ 20.41 | -1.4 % | $ 2.57 B | ||
|
Aptorum Group Limited
APM
|
4.89 | $ 0.79 | -6.51 % | $ 4.31 M | ||
|
Axsome Therapeutics
AXSM
|
273 | $ 165.07 | -0.79 % | $ 8.21 B | ||
|
I-Mab
IMAB
|
271 | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | ||
|
AbCellera Biologics
ABCL
|
173 | $ 3.76 | -1.7 % | $ 1.12 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
32 | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
245 | - | -18.52 % | $ 27.3 M | ||
|
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - | ||
|
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | ||
|
Acorda Therapeutics
ACOR
|
394 | - | -24.86 % | $ 820 K | ||
|
Certara
CERT
|
89.6 | $ 7.24 | 2.62 % | $ 1.16 B | ||
|
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | ||
|
Codexis
CDXS
|
50.2 | $ 1.01 | -0.98 % | $ 74.1 M | ||
|
Aeterna Zentaris
AEZS
|
115 | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
78.4 | - | -10.17 % | $ 12.2 K | ||
|
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | ||
|
Catalyst Pharmaceuticals
CPRX
|
178 | $ 23.77 | -0.46 % | $ 2.91 B | ||
|
Agenus
AGEN
|
4.13 | $ 3.27 | -2.09 % | $ 1.17 M | ||
|
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M | ||
|
Agios Pharmaceuticals
AGIO
|
1.74 K | $ 28.85 | -1.2 % | $ 1.67 B | ||
|
Champions Oncology
CSBR
|
66.5 | $ 5.98 | -1.48 % | $ 81.7 M | ||
|
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | ||
|
Завод ДИОД
DIOD
|
64.6 | - | - | - | ||
|
Фармсинтез
LIFE
|
9.78 | - | - | - | ||
|
Albireo Pharma
ALBO
|
40.8 | - | -0.23 % | $ 916 M | ||
|
Cellectis S.A.
CLLS
|
136 | $ 3.71 | -2.43 % | $ 116 M | ||
|
Altimmune
ALT
|
15.1 K | $ 4.22 | 1.32 % | $ 300 M | ||
|
Teligent, Inc.
TLGT
|
167 | - | -13.85 % | $ 16.1 M | ||
|
Viela Bio, Inc.
VIE
|
174 | - | - | $ 2.91 B | ||
|
Amarin Corporation plc
AMRN
|
213 | $ 14.3 | 2.66 % | $ 5.93 B | ||
|
AbbVie
ABBV
|
350 | $ 233.44 | -0.33 % | $ 413 B |